Biomedical (basic)
Ended Definitive Contract Awarded
- Contract number
- 00265199611D265972363
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $116,727
Award facts
- Contract value 28% obligated
-
- $0.00 Current, with exercised options
- $410,000.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Maryland, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $116,727 | |
| Original award | $0 |
About this award
Bioreliance Corporation's Life Sciences Services division received a $410,000 definitive contract award on September 24, 1998, for biomedical basic research services, with an ultimate completion date of November 29, 1999. The contract utilized cost-plus-fixed-fee pricing and was performed at the company's Rockville, Maryland facility. No small business set-aside was applied to this award, indicating the contract was competed in the open marketplace. As a subsidiary entity specializing in critical laboratory and testing services, Bioreliance provided essential microbiological and scientific testing capabilities to support federal health research initiatives, including endotoxin testing, sterility testing, and Limulus Amebocyte Lysate (LAL) testing for pharmaceutical and biotechnology applications.
This contract demonstrates Bioreliance's established role as a key service provider to federal health research institutions, including the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Centers for Disease Control and Prevention. The company's expertise in specialized testing methodologies and pharmaceutical product examination supported the agencies' drug development, vaccine research, and investigational new drug application processes. Bioreliance's track record of federal contracting, both as prime and subcontractor, reflects its competitive standing in the scientific testing marketplace and its critical contributions to federal biomedical research programs throughout the late 1990s and beyond.
Quick answers
Who was awarded contract 00265199611D265972363?
00265199611D265972363 was awarded to Bioreliance Corporation by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 24, 1998.
How much is contract 00265199611D265972363 worth?
The government has obligated $116,727 on 00265199611D265972363. Its potential value, with all options, is $410,000.
Was contract 00265199611D265972363 competed?
The extent of competition for 00265199611D265972363 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award